Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Presented Initial Phase 1 UNIVERSAL Trial Data on ALLO-715 at The American Society of Hematology (ASH) Meeting Providing First Proof-of-Concept for an AlloCAR T™ Therapy in Relapsed/Refractory...
-
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
-
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
-
Prestigious Prize Presented to Distinguish Leading-Edge Researchers in EuropeDr. Schumacher Recognized for the Development of Technologies to Study the Role of the Immune System in Cancer Progression...
-
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
-
Combination Represents One of Allogene’s Three Strategies to Target BCMA for Multiple MyelomaPhase 1 Clinical Trial Expected to Begin in the First Quarter of 2021 SOUTH SAN FRANCISCO, Calif., Dec. ...
-
Allogene Overland Biopharm, a First-of-its-Kind Collaboration in Allogeneic Cell Therapy, Is Dedicated to Making AlloCAR T™ Available to Patients in Greater China, Taiwan, South Korea and SingaporeThe...
-
ALLO-605 Demonstrated Enhanced Killing of Multiple Myeloma Cells and Persistence Relative to BCMA CAR TTurboCAR Technology Represents a Key Component to the Company’s Three-Pronged Clinical Strategy...
-
Results Demonstrate Ability of AlloCAR T™ Therapy to Selectively Kill CD70 Expressing Leukemic CellsCoupled with Previous Findings in Renal Cell Carcinoma (RCC), Results Highlight the Potential of...
-
First Reported Allogeneic CAR T Data in Multiple Myeloma Highlights Initial Safety and Efficacy in Heavily Pretreated, Refractory PatientsIn the Ongoing Study, 31 Patients Were Evaluable for Safety...